Abstract 1059P
Background
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under pathological conditions. However, the clinical implications of localization and maturation stage of TLS in clear cell renal cell carcinoma (ccRCC) remain to be elucidated.
Methods
Immunohistochemistry and multispectral fluorescent were used to evaluate the TLS heterogeneity along with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic and immunological implications of the TLS heterogeneity in 625 patients with ccRCC from multiply cohorts. Associations between TLS heterogeneity and immunologic activities were assessed by the quantification of immune cells infiltration.
Results
TLS typically comprises B-cell follicles with germinal centers and are surrounded by T-cell zones and dendritic cells. TLS infiltrates were identified in 34.2% of the ccRCC samples. A higher proportion of early TLS was found in peritumoral TLS, while intratumoral TLS mainly comprised secondary follicle-like. Kaplan-Meier analyses indicated that the presence of intratumoral TLS markedly correlated with both superior progression-free survival PFS and OS, while the presence of peritumoral TLS showed the opposite predictive trends for outcomes. Notably, presence of TLS, especially intratumoral TLS and mature TLS (namely SFL-TLS, with CD23+ germinal center) significantly correlated with better clinical outcomes and objective reflection rate for ccRCC patients receiving immunotherapies. Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of PD-L1+ tumor-associated macrophages and Treg infiltration in the peritumoral regions increased prominently, showing a typical suppressive TME characterizations.
Conclusions
In conclusion, this study for the first time revealed the implications of TLS localization and maturation heterogeneity on the clinical outcomes and immunological status and responses of ccRCC, allowing the identification of immunophenotypes and the improvement of immunotherapeutic effectiveness for ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Presenter: Bilal Krayim
Session: Poster session 19
1344P - A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
Presenter: Jorge Nieva
Session: Poster session 19
1345P - Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
Presenter: Melissa Junttila
Session: Poster session 19
1346P - Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
Presenter: Xiaoyan Li
Session: Poster session 19
1348P - Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies
Presenter: Yun-Gyoo Lee
Session: Poster session 19
1349P - Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
Presenter: Molly Li
Session: Poster session 19
1350P - Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib
Presenter: Takehiro Tozuka
Session: Poster session 19
1351P - Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Presenter: Dan Tao
Session: Poster session 19
1352P - Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC
Presenter: Ruyun Gao
Session: Poster session 19